EnSilica PLC (LSE:ENSI) has followed a step change in its financial performance with a fresh customer win. On 29 October 2026 the semiconductor specialist announced a US$2.4 million contract to develop and Supply an application-specific integrated circuit for a US healthcare technology company, and confirmed it had completed the tape-out of a next-generation chip for a UK life sciences customer. The news came weeks after final results showing Revenue up by more than half.
Company Overview
EnSilica designs and supplies application-specific integrated circuits, known as ASICs, for customers in sectors including healthcare, satellite communications and industrial markets. It describes itself as having transitioned into a semiconductor design and supply platform.
Its model combines engineering fees for chip development with longer-term revenue from supplying chips once they enter Volume production. In its latest results the company said five of its ASICs were in volume production and fourteen were in design. This pipeline of chips at different stages shows how LSE:ENSI is building a base of recurring supply alongside new design projects.
Engineering fees are paid while a chip is being designed, whereas supply revenue arrives once the customer product is manufactured and sold, often over many years. Lifetime supply visibility is reported alongside annual results for this reason.
Latest Developments
The new US$2.4 million contract covers a wireless biosensing and therapeutic controller chip, and EnSilica said the project offers potential for substantial long-term supply volumes. The completed tape-out, a key milestone in the chip development process, relates to a previously announced US$1.6 million contract, with the majority of the revenue expected in the current financial year and potential for future production supply.
A tape-out is the point at which a finished chip design is released for manufacturing. It marks the end of the design phase and the beginning of the process in which prototypes are produced and tested before any move to volume supply.
Earlier announcements this year point to growing activity across its markets. In July 2026 the company reported follow-on satellite orders, and on 3 August it announced a second-phase contract win and a new project update. On 8 September 2026 it announced an EU space and communications centre of excellence. Shareholders approved all resolutions at the Annual General Meeting on 30 October 2026.
Financial Picture
In final results published on 5 October 2026, covering the year ended 31 May 2026, EnSilica reported revenue of £27.8 million, up 53%. EBITDA rose to £5.9 million, compared with roughly break-even in the prior year. The company said its lifetime supply visibility had increased by 50% to US$375 million, and that its sales pipeline had also risen by 50% to more than US$600 million.
Lifetime supply visibility of US$375 million represents the value of chip supply that the company expects over the life of its customer programmes, so it should be read as an estimate rather than as contracted revenue. The move in EBITDA from roughly break-even to £5.9 million shows how revenue growth has translated into operating earnings.
The group strengthened its Balance Sheet through two oversubscribed share placings: £10 million in March 2026 and a further £14.9 million after the year end, completed in July 2026 alongside a retail offer of up to £1 million. EnSilica said the funds would accelerate pipeline conversion and expand engineering capacity.
Management described the Business as positioned for continued momentum but did not give specific numerical guidance. As a growth-focused company reinvesting in expansion, EnSilica has not been a Dividend payer.
The retail offer of up to £1 million was designed to allow smaller shareholders to take part alongside the institutional placing, a feature that AIM companies often use to widen participation.
Sector and index Context
EnSilica is one of a small number of UK-listed chip design companies and a constituent of the FTSE AIM All Share Index. Demand for custom silicon has been supported by growth in connected medical devices, satellite communications and industrial automation.
Custom chips are designed for a specific purpose, which can allow customers to achieve the performance and power characteristics they need in a smaller device. That is why sectors such as wearable healthcare technology and space communications have been active areas for LSE:ENSI and its peers.
Factors to Monitor
ASIC programmes take several years to move from design to volume production, so the timing of supply revenue depends on customer programmes. The business works with a limited number of key customers and relies on third-party foundries to manufacture its chips. Lifetime supply visibility figures depend on customers' products reaching their expected volumes. The share placings have increased the number of shares in issue, and expanding engineering headcount will add to costs as the company builds capacity.
What to Watch Next
Market participants will watch for further contract wins and conversion of the US$600 million-plus pipeline, progress in moving the fourteen chips in design towards volume production, and a trading update or interim results for the six months to 30 November 2026, which will show whether the growth reported last year is being maintained. Announcements from LSE:ENSI on its healthcare and satellite programmes will be of particular interest.


_11_16_2026_12_57_37_326443.jpg)



Please wait processing your request...